1. Introduction The increasing burden of multidrug-resistant tuberculosis (MDR TB) is a major threat to global tuberculosis control. In 2014, approximately 4,80,000 people were reported to have developed MDR-TB, globally. The widespread incidence of MDR TB is attributed to suboptimal treatment options and poorly managed quality and supply of drugs. This condition is resistant to key drugs used to treat tuberculosis (isoniazid and rifampicin), and thus, presents with additional challenges for treatment.
Currently followed management plan, based on the guidelines provided by WHO, includes treating MDR TB with various groups of drugs that were classified based on their efficacy and drug class. This treatment usually lasts longer than 18 months. The treatment adherence is low and the reported success rates were 48% in 2012 and 54% in 2017. Therefore, with an aim to develop a working…
